Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients

  • Deciphera Pharmaceuticals Inc DCPH announced an exploratory analysis of data from the INTRIGUE Phase 3 study of Qinlock using circulating tumor DNA (ctDNA).
  • The data comes from a subgroup of patients with gastrointestinal stromal tumors (GIST) previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only.
  • Patients with mutations in KIT exon 11 and exon 17/18 only had substantially improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) with Qinlock versus Pfizer Inc's PFE Sutent (sunitinib). 
  • Related: Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer.
  • The median progression-free survival for Qinlock of 14.2 months versus sunitinib of 1.5 months.
  • The objective response rate of 44.4% for Qinlock versus 0% for sunitinib.
  • The median overall survival for Qinlock was not estimable versus 17.5 months for sunitinib.
  • The company plans to initiate the INSIGHT pivotal Phase 3 study of Qinlock versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only in 2H of 2023.
  • Separately, Deciphera posted interim Q4 sales of approximately $36 million and FY22 revenue of approximately $134 million
  • Qinlock net product revenue is estimated to be approximately $33 million.
  • A cash balance of $339 million is expected to provide a runway into 2025.
  • Price Action: DCPH shares are up 2.82% at $16.39 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!